STAGE III COLON CANCER AJCC V8
Clinical trials for STAGE III COLON CANCER AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE III COLON CANCER AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE III COLON CANCER AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail aims to stop BRAF colon cancer in its tracks
Disease control OngoingThis study tests whether adding two targeted drugs (encorafenib and cetuximab) after standard surgery and chemotherapy can lower the chance of cancer coming back in people with a specific genetic type of stage II/III colon cancer (BRAF V600E). Participants either receive the drug…
Matched conditions: STAGE III COLON CANCER AJCC V8
Phase: PHASE2, PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated May 17, 2026 10:41 UTC
-
Experimental combo targets Hard-to-Treat HER2 cancers
Disease control OngoingThis early-phase trial tests whether adding ceralasertib to the targeted therapy trastuzumab deruxtecan (DS-8201a) is safe and effective for people with advanced solid tumors that have HER2 mutations. About 51 adults with various cancers (breast, stomach, colon, and others) will …
Matched conditions: STAGE III COLON CANCER AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 10:28 UTC
-
New hope for hard-to-treat colorectal cancer: drug duo targets tumor defenses
Disease control OngoingThis study tests a combination of two drugs—SX-682 and nivolumab—in people with a specific type of advanced colorectal cancer (RAS-mutated, MSS) that has spread or can't be removed. The goal is to see if the combination is safe and can shrink tumors or slow their growth. About 51…
Matched conditions: STAGE III COLON CANCER AJCC V8
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 17, 2026 10:26 UTC
-
Immunotherapy combo may keep stage III colon cancer at bay
Disease control OngoingThis study tests whether adding the immunotherapy drug atezolizumab to standard chemotherapy can better prevent colon cancer from coming back in people with stage III colon cancer that has a specific DNA repair problem (dMMR). About 712 participants will receive either chemothera…
Matched conditions: STAGE III COLON CANCER AJCC V8
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 12, 2026 13:42 UTC
-
New drug cocktail shows promise for Tough-to-Treat colorectal cancer
Disease control OngoingThis study tests whether adding two targeted drugs (LY3214996 and abemaciclib) to the standard drug cetuximab can shrink tumors or slow cancer growth in people with advanced colorectal cancer that no longer responds to cetuximab alone. About 46 adults with metastatic or inoperabl…
Matched conditions: STAGE III COLON CANCER AJCC V8
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 11, 2026 20:52 UTC
-
Immunotherapy boost may tame tough colorectal cancer
Disease control OngoingThis study is for people with advanced colorectal cancer that has a specific genetic change (BRAF V600E) and has not responded to prior treatment. It compares the usual two-drug therapy (encorafenib and cetuximab) against the same two drugs plus an immunotherapy drug called nivol…
Matched conditions: STAGE III COLON CANCER AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 04, 2026 16:19 UTC
-
The hidden cost of beating cancer: new study tracks financial toll on patients
Knowledge-focused OngoingThis study follows 565 people with stage I-III colon or rectal cancer who are being treated with the goal of a cure. Researchers track how treatment affects patients' finances and quality of life over 12 months. The goal is to help doctors understand the financial burden of cance…
Matched conditions: STAGE III COLON CANCER AJCC V8
Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Knowledge-focused
Last updated May 17, 2026 10:27 UTC